Sarah B. Goldberg

Sarah B. Goldberg

Auto-generated profile, based on publicly available information

Sarah B. Goldberg

Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
SGSarah B Goldberg
Sarah B Goldberg
SGScott N Gettinger
Scott N Gettinger
AMAmit Mahajan
Amit Mahajan
ACAnne C Chiang
Anne C Chiang
RHRoy S Herbst
Roy S Herbst
HKHarriet M Kluger
Harriet M Kluger

1 May 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
SGSarah B Goldberg
Sarah B Goldberg
KSKurt A Schalper
Kurt A Schalper
SGScott N Gettinger
Scott N Gettinger
AMAmit Mahajan
Amit Mahajan
RHRoy S Herbst
Roy S Herbst
HKHarriet M Kluger
Harriet M Kluger

24 June 2021 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MGMichael J. Grant
Michael J. Grant
RHRoy S. Herbst
Roy S. Herbst
SGSarah B. Goldberg
Sarah B. Goldberg

17 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MNMarcelo V. Negrao
Marcelo V. Negrao
HAHaniel A. Araujo
Haniel A. Araujo
GLGiuseppe Lamberti
Giuseppe Lamberti
ACAlissa J. Cooper
Alissa J. Cooper
NANeal S. Akhave
Neal S. Akhave
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non–small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups and captured ∼50% of those with early disease progression (progression-free survival ≤3 months) with KRASG12Ci. Pathway-level integration of less prevalent coalterations in functionally related genes nominated PI3K/AKT/MTOR pathway and additional baseline RAS gene alterations, including amplifications, as candidate drivers of inferior outcomes with KRASG12Ci, and revealed a possible association between defective DNA damage response/repair and improved KRASG12Ci efficacy. Our findings propose a framework for patient stratification and clinical outcome prediction in KRASG12C-mutant NSCLC that can inform rational selection and appropriate tailoring of emerging combination therapies. Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501

26 September 2013 in The Oncologist
Verified
Journal Article
Closed access
PDF file
SGSarah B. Goldberg
Sarah B. Goldberg
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
SDSubba Digumarthy
Subba Digumarthy
AMAlona Muzikansky
Alona Muzikansky
DJDavid M. Jackman
David M. Jackman
LSLecia V. Sequist
Lecia V. Sequist
Purpose.: Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer has an oncogene-addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Published data suggest that EGFR addiction persists after development of TKI acquired resistance, leading many clinicians to continue TKI with subsequent chemotherapy; however, this strategy has not been formally evaluated. Methods.: We retrospectively reviewed an institutional database to identify patients with advanced EGFR mutation with acquired resistance who subsequently received chemotherapy. Patients were classified as receiving chemotherapy with continued erlotinib or chemotherapy alone. We assessed differences in outcomes between the two strategies. Results.: Seventy-eight patients were included, 34 treated with chemotherapy and erlotinib and 44 treated with chemotherapy alone. Objective response rate was evaluable in 57 patients and was 41% for those treated with chemotherapy and erlotinib and 18% for those treated with chemotherapy alone. After adjusting for chemotherapy regimen and length of initial TKI course, the odds ratio for the response rate was 0.20 (95% confidence interval: 0.05–0.78; p = .02) favoring treatment with chemotherapy and erlotinib. The median progression-free survival was 4.4 months on chemotherapy and erlotinib and 4.2 months on chemotherapy alone (adjusted hazard ratio = 0.79; 95% confidence interval: 0.48–1.29; p = .34). There was no difference in overall survival. Conclusion.: This is the first study, to our knowledge, to demonstrate that continuation of EGFR TKI with chemotherapy in patients with acquired resistance improves outcomes compared with chemotherapy alone. We observed an improved response rate but no difference in progression-free survival or overall survival. A larger prospective clinical trial is needed to evaluate this promising strategy further.

6 October 2023 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PSPaul Stockhammer
Paul Stockhammer
MGMichael Grant
Michael Grant
AWAnna Wurtz
Anna Wurtz
GFGiorgia Foggetti
Giorgia Foggetti
FEFrancisco Expósito
Francisco Expósito
SGSarah B. Goldberg
Sarah B. Goldberg
Patients with metastatic EGFR-mutant NSCLC inevitably have disease progression while on TKI therapy. Co-occurring tumor suppressor gene (TSG) alterations have been associated with poor outcomes, however, detailed analyses of their impact on patient outcomes are limited. Patients with EGFR-mutant NSCLC treated with EGFR-TKIs who had tumor genomic profiling were included. Alterations in TP53 and five additional TSGs (RB1, NF1, ARID1A, BRCA1 and PTEN) were used to stratify the cohort into three subgroups: patients with tumors harboring a TP53 mutation plus a mutation in ≥1 additional TSG (TP53mut/TSGmut), a TP53 mutation without additional TSG mutations (TP53mut/TSGwt), and TP53wt. Patient characteristics and clinical outcomes were assessed in two independent cohorts. 101 patients from the Yale Cancer Center and 182 patients from the AACR Project GENIE database were included. In the Yale cohort, TP53 mutations were identified in 65 (64%) cases (of which 23 were TP53mut/TSGmut and 42 were TP53mut/TSGwt). Although the presence of a TP53 mutation was associated with worse outcomes, the additional TSG alteration in TP53mut tumors identified a subset of patients associated with particularly aggressive disease and inferior clinical outcome in both the Yale and the GENIE cohort. Specifically, in the Yale cohort for patients receiving first-line TKI, those with TP53mut/TSGmut tumors had shorter PFS and OS than TP53mut/TSGwt (PFS: HR 2.03, CI 1.12 - 3.69, P<0.01, OS: HR 1.58, CI 0.82 - 3.04, P=0.12) or TP53wt cases (PFS: HR 2.4, CI 1.28 - 4.47, P<0.001, OS: HR 2.54, CI 1.21 - 5.34, P<0.005). Inferior outcomes in TP53mut/TSGmut tumors were also seen in patients receiving osimertinib as second-line therapy. Patients with TP53mut/TSGmut tumors represent a patient subgroup characterized by an aggressive disease phenotype and inferior outcomes on EGFR-TKIs. This information is important for understanding the biologic underpinnings of differential outcomes with TKI treatment and has implications for identifying patients for additional therapeutic interventions beyond osimertinib monotherapy.